HTB

Pregnancy

Steady state PK of nelfinavir and M8 in pregnancy

Post partum complications in HIV-positive women

Nevirapine, pregnancy and adverse events

Conflicting findings with HAART use in pregnancy and prematurity

Antiretrovirals, mode of delivery and transmission risk

Intrauterine exposure to efavirenz

Use of rapid HIV tests in labour

Eighteen-month findings of HIVNET 012

MTCT-Plus operates in Cote D’Ivoire, Kenya, Mozambique, Rwanda, South Africa, Thailand, Uganda and Zambia

Postnatal transmission of HIV to breastfed infants following short course ZDV regimen

Subtype differences in mother to child transmission

Influence of mothers’ health and survival on children’s survival

Single-dose nevirapine resistance in over 75% of mothers

Nevirapine and MTCT: the single-dose backlash

Pharmacology studies at the 2nd IAS conference

Maternal health, transmission and fertility

Pregnancy-related PK studies

Pediatric studies from 10th CROI

Nevirapine resistance – the cautionary tales continue

Study of MTCT programme finds resistance in women on two doses of monotherapy

Antiretroviral use in pregnancy and the risk of an adverse outcome

Complications may outweigh benefits of Caesarian delivery

Complex therapy reduces vertical transmission risk

Reduction of mother to child HIV-1 transmission: breastfeeding negates benefits of short course regimens

Nevirapine at the centre of MTCT controversy

Mothers, orphans, and prevention of paediatric AIDS

Pregnancy: growing body of evidence supports treating maternal disease

Resistance to nevirapine differs by HIV-1 subtype

Uganda to offer free HIV drugs to pregnant women to prevent vertical HIV transmission

Breastfeeding may increase maternal mortality among HIV-positive women, study shows

Prevalence of the T215Y mutation in HIV type 1-infected pregnant women in a New York cohort, 1995-1999

Lactic acidosis in pregnant women receiving d4T (stavudine) and ddI (didanosine): EMEA issue statement

US perinatal treatment guidelines updated

HIV and women – overview

US FDA and Bristol-Myers Squibb issue caution for combination HIV therapy with stavudine (d4T) and didanosine (ddI) in pregnant women

Is the chance to cut a chance to cure? The Caesarean section controversy revisited

Protease inhibitors safe and effective in HIV-positive pregnant women

Pregnancy does not accelerate progression of HIV-1 infection

Mother-to-child transmission, maternal health and women’s access to care

The M in MTCT: questions about HIV-positive mothers

HIV-positive women, pregnancy and newborns

Post navigation